# QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer

> **NCT07733115** · PHASE2 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **BIOLOGICAL:** Iparomlimab and Tuvonralimab (QL1706)
- **DRUG:** Gemcitabine and Cisplatin Chemotherapy

## Key facts

- **NCT ID:** NCT07733115
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733115, "QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*